Merck’s Ervebo Vaccine Receives the US FDA’s Approval for Prevention of Ebola Virus

 Merck’s Ervebo Vaccine Receives the US FDA’s Approval for Prevention of Ebola Virus

Merck’s Zerbaxa (ceftolozane and tazobactam) Receives FDA’s Approval for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia in Adults

Shots:

  • The approval is based on the study conducted in Guinea during the 2014-2016 outbreak in individuals 18 years of age and older evaluated 3,537 contacts with laboratory-confirmed EVD who received either “immediate” or 21-day “delayed” vaccination with Ervebo
  • The study showed that Ervebo was 100% effective in preventing Ebola cases with symptom onset >10 days post-vaccination and no cases of EVD with symptom onset >10 days were observed in the “immediate” cluster group, vs 10 cases of EVD in the 21-day “delayed” cluster group
  • Ervebo is the first FDA-approved vaccine targeted for Ebola virus disease (EVD) in adults which is caused by Zaire ebolavirus and has been reviewed under Priority Review and a Tropical Disease Priority Review Voucher also received FDA’s BT designation

Click here to read full press release/ article | Ref: The US FDA | Image:

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post